Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4109208 | 0.98 | ATM (0.35) | ATMPARP1L3MBTL1ALDH1A1 | |
| SCHEMBL2167672 | 0.80 | ATM (0.33) | ATM | |
| SCHEMBL3634948 | 0.80 | LMNA (0.36) | ATMPARP1L3MBTL1ALDH1A1 | |
| SCHEMBL3635465 | 0.78 | L3MBTL1 (0.37) | ATMPARP1L3MBTL1ALDH1A1 | |
| SCHEMBL28321078 | 0.76 | ATM (0.32) | ATMPARP1L3MBTL1ALDH1A1 | |
| SCHEMBL472332 | 0.76 | ALDH1A1 (0.42) | L3MBTL1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL9698155 | 0.76 | L3MBTL1 (0.35) | ATMPARP1L3MBTL1ALDH1A1 | |
| SCHEMBL4637388 | 0.74 | L3MBTL1 (0.34) | ATMPARP1L3MBTL1ALDH1A1 | |
| Carbamic Acid SCHEMBL15206061 | 0.73 | ATM (0.42) | ATMPARP1L3MBTL1ALDH1A1 | |
| SCHEMBL844602 | 0.71 | ATM (0.32) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2001288-B1 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | SYNGENTA LTD (GB) | 2015-06-24 | — | — | EP | disclosed |
| US-8420859-B2 | Formulations | SYNGENTA LIMITED (GB) | 2013-04-16 | — | — | US | disclosed |
| US-20090227453-A1 | FORUMLATIONS | SYNGENTA LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| CN-101404879-A | Process for producing lactamide compound, novel lactamide compound and preparation containing lactamide compound | SYNGENTA LTD (GB) | 2009-04-08 | — | — | CN | disclosed |
| EP-2001288-A2 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | Syngenta Limited (GB) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007107745-A2 | PROCESS FOR PRODUCING LACTAMIDE COMPOUNDS, NEW LACTAMIDE COMPOUNDS AND FORMULATIONS CONTAINING LACTAMIDE COMPOUNDS | SYNGENTA LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227453-A1 | FORUMLATIONS | CBR3, NR1H3, NR2C2 | ATM 3331/4885PARP1 4658/4885L3MBTL1 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.